Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Novel Test Device Diagnoses Dengue

By LabMedica International staff writers
Posted on 06 Feb 2012
An immunochromatographic test device is intended for the rapid detection of immunoglobulin A (IgA) antibodies to dengue virus in human serum, plasma, or whole blood. More...


The test is based on the capture of specific dengue antibodies using immobilized dengue virus (DENV) serotype 2 antigen and the subsequent detection of the captured immunoglobulin using goat anti-human IgA conjugated to colloidal gold.

Scientist at the Instituto Politécnico Nacional (Mexico City, Mexico) compared the immunochromatographic test device known as the ASSURE Dengue IgA Rapid test with other commercial tests. A total of 225 sera were used for the evaluation; One hundred and seventy-two sera were collected during the years 2009 and 2010 from dengue patients in regional public health diagnosis laboratories as part of the national surveillance program for dengue in Mexico and 47 sera were collected from healthy blood donors.

ASSURE Dengue IgA Rapid Test (MP Diagnostics; Solon, OH, USA) is an indirect solid-phase immunochromatographic assay where antibodies in the test sample (serum, plasma or whole blood) form antibody-antigen complexes with immobilized-antigen on the membrane as the test sample migrates upwards from the sample well. The bound antibody-antigen complexes are subsequently detected by anti-human IgA conjugated to colloidal gold. The control line contains protein L that binds with human IgA and the anti-human IgA-colloidal gold conjugate, and serves as an indication of proper sample addition.

The ASSURE test detected as positive for IgA 105/172 (61.0%) of the dengue sera tested, while the Dengue IgM Capture ELISA (PanBio, Sinnamon Park, Queensland, Australia) detected as positive for IgM, 93/172 (54.1%) of the sera. The overall specificity and sensitivity of the ASSURE test were 85.1% and 61.0%, respectively. The positivity rate for IgA went from 33.3% for sera collected the same day of fever onset to 81.2% for sera collected five days after fever onset. Infections with serotype 2 viruses were detected more efficiently than those with serotype 1 viruses were, and no sera from infections with serotypes 3 and 4 were available. The kit was twofold more efficient at detecting secondary infections than at detecting primary infections.

The authors concluded that the rapid test based on immunochromatography required few facilities to be carried out and are very suitable to be applied on single samples. The implementation of immunochromatographic assays in field locations or point-of-care sites may be a valuable alternative to test for early diagnosis of dengue. The study was published in the February 2012 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Instituto Politécnico Nacional
MP Diagnostics
PanBio



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.